eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors

SAN DIEGO, January 6, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that dosing has begun in a Phase 1/2 dose-escalation and cohort-expansion study of eFT508 in patients with advanced solid tumors. eFT508 is the company’s potent, highly selective oral inhibitor of MNK1 and MNK2.

“Initiation of this first clinical trial of eFT508 marks an important milestone for the program, our scientific founders and the company,” saidSteve Worland, Ph.D., president and CEO of eFFECTOR. “We look forward to demonstrating target engagement, identifying a recommended Phase 2 dose and initiating expansion cohorts in specific solid tumor types during 2016. We also expect to open a second clinical trial of eFT508 in patients with lymphoma in the coming months.”

The Phase 1/2 trial is evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral eFT508 in patients with advanced solid tumors. The primary endpoint for the dose-escalation portion of the study is the maximum tolerated dose (MTD) and/or recommended dose (RD). The primary endpoint for the cohort-expansion portion of the study is overall response rate (ORR) in patients with specific tumor types. Pharmacodynamic markers to be measured include phosphorylation of eIF4E, a key component of the translation initiation complex, and levels of translationally regulated tumor-driving proteins that were previously identified using eFFECTOR’s platform technology.

Additional information about the clinical trial can be found on the ClinicalTrials.gov website at the following link: https://clinicaltrials.gov/ct2/show/NCT02605083.

Heidi Chokeir, Ph.D.